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Rare disease patient organisations have a tendency to be
deeply involved in research development and infrastruc-
tures, and are practiced at founding strategic alliances
with clinical and research networks [1]. In building an
integrated platform for rare disease databases, registries,
biobanks and bioinformatics through the RD Connect
project, we wanted to explore explicitly and in detail, the
inclusion of rare disease patients and their advocates in
RD Connect’s core activities.
RD Connect collaborates closely with two related
research projects EURenOmics (rare kidney disease) and
Neuromics (rare neuromuscular/neurodegenerative
disease) both of which utilise genomic technologies
to improve care and therapies for specific disease groups.
A workshop of 45 clinicians, scientists and patients/
advocates from RD Connect, EURenOmics and Neuro-
mics, identified two areas of concern. The first were proce-
dural, around the inclusion of patients in governance
including: on-going dialogue between researchers
and patients; mutual education; and reporting and
dissemi nation. The second set were contemporary ethical,
legal and social issues (ELSI), around privacy, informed
consent, data sharing, return of results and incidental
findings. A review of the literature found that rare disease
patients’ views on these contemporary issues are rarely
documented.
To explore these two areas we have parallel initiatives
designed to include patients through membership of
boards and committees at the highest levels and via a spe-
cific research strand investigating ELSI. Through including
patients in governance, RD Connect fulfils the top level of
Arnstein’s ladder of participation, that of citizen control,
whereby those who the governance structure serves are
represented in decision making [2]. Among other things,
a Patient Advisory Committee works to discuss and build
consensus on issues affecting patients and a Patient and
Ethics Council promotes dialogue on ELSI between
patients/advocates and researchers within RD Connect,
Neuromics and EURenOmics.
In our research strand we are exploring patient hopes,
expectations, concerns and fears for the creation of an
integrated platform for rare disease databases, registries
and biobanks in a series of focus groups and a Delphi
exercise. Using the notion of communities of practice,
which encourage collective learning through shared
endeavour, we aim to use the findings from this
research to inform discussion and education activities
which will enable patient perspectives to be embedded
into the work of RD Connect, EURenOmics and Neuro-
mics [3]. Bearing in mind that patient organisations and
scientific groups may have different decision making
mechanisms, we will experiment with creating spaces to
allow meaningful, on-going dialogue between patients/
advocates and researchers [4].
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